AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Zymeworks to Discontinue ZW171 Clinical Development
ByAinvest
Tuesday, Sep 2, 2025 6:45 am ET1min read
Zymeworks has discontinued clinical development of ZW171, a product candidate for cancer treatment. The company has a pipeline of four preclinical candidates, including ZW191, ZW220, and ZW251, and is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Zymeworks' platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT.
VANCOUVER, British Columbia, Sept. 02, 2025 — Zymeworks Inc. (Nasdaq: ZYME) has announced the discontinuation of clinical development for ZW171, a T cell engager targeting mesothelin-driven cancers. The decision follows the completion of Phase 1 trial dose escalation cohorts in ovarian cancer and non-small cell lung cancer patients. While cytokine release syndrome was manageable, the trial revealed dose-limiting toxicities related to mesothelin-targeted effects [1].Zymeworks determined that further dose evaluation would not support a favorable benefit-risk profile. The company is redirecting resources to more promising candidates, including ZW191 (currently in Phase 1), ZW251 (planned Phase 1 study in 2025), and ZW209 (IND filing planned for early 2026) [1].
The termination of ZW171 represents a significant setback in Zymeworks' oncology pipeline. The mesothelin-targeting T cell engager was being evaluated for gynecological, thoracic, and digestive system cancers, all areas with substantial unmet needs. The critical issue identified was an unfavorable benefit-risk profile due to dose-limiting toxicities consistent with mesothelin-related on-target off-tumor effects [1].
Zymeworks continues to advance its pipeline, leveraging its expertise in antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The company's platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT [1].
References:
[1] https://www.stocktitan.net/news/ZYME/zymeworks-announces-decision-to-discontinue-clinical-development-of-qezs3habk5i6.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet